Journal of Medicinal Chemistry
Article
a Dionex Summit dual-gradient HPLC instrument, equipped with a
four-channel UV−vis detector, using a Vydac 218TP54 column (250 ×
4.6 mm, 5 μm, flow rate at 1.5 mL/min). Mobile phases A (aqueous
0.1% trifluoroacetic acid (TFA)) and B (90% aqueous acetonitrile
containing 0.1% TFA) were used for preparing binary gradients. All
analyses were carried out under gradient conditions (10−50% B in 20
min, except as otherwise indicated). All crude peptides were purified to
95% or more homogeneity for analytical and other experimental
purposes. Semipreparative HPLC was carried out on a Shimadzu series
LC-6A chromatograph, equipped with two independent pump units, a
UV−vis detector, and a Vydac 218TP1022 column (250 × 22 mm, 10
μm, flow rate at 15 mL/min). Elutions were carried out by the same
mobile phases described above. All the purified peptides were analyzed
again by HPLC and HRMS. Mass spectral analyses were carried out on
a Mariner API-TOF workstation (PerSeptive Biosystems Inc.),
operating with ESI techniques in positive mode. NMR spectra were
recorded on a Varian Gemini 300 spectrometer (300 and 75.5 MHz
for 1H and 13C, respectively). UV−vis spectra were recorded at rt on a
Shimadzu UV-2501PC spectrophotometer or on a Lambda 5
spectrophotometer (Perkin-Elmer), in 0.1 or 1 cm quartz cells.
Chemical Synthesis. 19-Glutaramide-2,7,12,17-tetraphenylpor-
phycene (2b). A 44 mg (0.1 mmol) sample of 2a was dissolved in 14
mL of THF and combined with 14 mL of methanol, and 9 mL of 4 N
aqueous sodium hydroxide was added dropwise with stirring at rt
within 5 min. The reaction was stirred for an additional 45 min,
neutralized, and then precipitated under acidic conditions with the
complete addition of 50 mL of ice-cold 5% acetic acid. The flaky
precipitate was filtered, washed with water and then with water/
methanol (1:1), and dried. The title compound was obtained in the
be able to diffuse into the cell to inflict damage to the vital
structure.1,40 Our photophysical data thus support this
hypothesis.
Testing the above PS against MRSA reveals a number of
differences relative to E. coli. First, except for the porphycene,
the concentration needed to inactivate bacteria was 1 order of
magnitude lower. Interestingly, the porphycene conjugate was
almost equally active against both kinds of bacteria. The higher
susceptibility of Gram-positive bacteria to photodynamic
damage has long been known for a large number of PSs.41
Second, it is interesting to recall that washings did not
appreciably remove 1b and its conjugates (1c and 1d) from the
cells (Figure 7), nor did it decrease the photodynamic
inactivation of MRSA (Figure S7, Supporting Information).
In addition, the nonconjugated porphyrin 1b was the most
active PS. This probably can be related to its more hydrophobic
character, which helps in penetration of the cell wall and the
cytoplasmic membrane of Gram-positive bacteria. The
porphycene 2a was probably too hydrophobic, and its strong
aggregation in the external medium prevented cell entrance.
Concerning PSs 4b and 4e, the observations are similar to
those of E. coli: the nonconjugated PS 4b is more active than 4e
1
on account of its lower ability to quench O2, and both lose
their activity after washings due to the very poor binding to the
bacterial cells (Figure 7).
1
CONCLUSIONS
form of a dark green powder. Yield: 27 mg (70%). H NMR (400
■
MHz, DMSO-d6): δ = 12.10 (br s, 1H), 10.96 (s, 1H), 10.08 (s, 1H),
10.07 (s, 1H), 10.05 (s, 1H), 9.93 (d, J = 12, 1H), 9.91 (d, J = 12, 1H),
9.85 (s, 1H), 9.82 (s, 1H), 8.37 (m, 6H), 7.98 (d, J = 8, 2H), 7.88 (m,
5H), 7.74 (m, 5H), 7.60 (m, 2H), 4.29 (s, 1H), 3.93 (s, 1H), 2.25 (t, J
= 8, 2H), 2.16 (t, J = 8, 2H), 1.72 (q, J = 8, 2H). 13C NMR (100 MHz,
DMSO-d6): δ = 174.1, 171.9, 158.0, 144.7, 143.7, 142.8, 142.7, 141.3,
139.1, 137.7, 135.6, 135.4, 135.3, 134.8, 134.3, 133.3, 132.8, 131.1,
131.0, 130.3, 129.2, 129.2, 129.1, 128.0, 127.4, 127.1, 123.1, 125.0,
124.5, 116.0, 115.5, 113.9, 33.9, 33.06, 19.8. HRMS (ESI-TOF): m/z
calcd for C49H38N5O3 744.2969 [M + H]+, found 744.2970.
The search for more effective antimicrobial PSs has led to a
number of strategies. Among them, binding to an antimicrobial
peptide offers the attractive prospect of enhancing both the
water solubility of the PS and the efficiency of the PDT
treatments through a synergistic effect. In this work we have
compared a number of free and apidaecin-conjugated PSs
differing in structure and charge. Our results confirm previous
findings that the conjugation of per se ineffective highly
hydrophobic PSs to a cationic peptide produces a photo-
sensitizing agent effective against Gram-negative bacteria.
MRSA are even more susceptible to the action of conjugates,
which produce the same reduction of bacterial growth at one-
tenth the concentration. The apidaecin ability to penetrate
Gram-negative bacteria is unfortunately lost after conjugation
to a bulky PS, but the amphiphilic character conferred by the
peptide enforces the binding of the PS to the bacterial outer
membrane. Apidaecin−PS conjugates appear most promising
for treatment protocols requiring repetitive washing after
sensitizer delivery, where the most active cationic PSs, such
as 4b and its apidaecin conjugate 4e, are rapidly washed out.
On the other hand, apidaecin cannot improve the phototoxic
activity of the cationic porphyrin, which is mainly determined
by a very high yield of singlet oxygen production in the
surroundings of the bacterial outer membrane.
Synthesis of PS−Peptide Conjugates (General Procedure). The
peptide sequences were prepared on an automated Advanced
Chemtech 348Ω peptide synthesizer, on a 0.25 mmol scale, starting
from Fmoc-Leu-Wang (substitution 0.6 mmol/g of resin). The tert-
butyl group and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
group were used to protect tyrosine and arginine side chains,
respectively, and the trityl group to protect asparagine and histidine
side chains. Fmoc deprotection was achieved with 20% piperidine in
DMF (5 + 15 min). Couplings were performed in the presence of O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophos-
phate/N-hydroxybenzotriazole/N,N-diisopropylethylamine (reaction
time 45−60 min), using an excess of 4 equiv of the carboxyl
component. After the coupling of the last amino acid and removal of
the Fmoc group, the resin was washed with DMF and CH2Cl2 and
then dried under vacuum. The dried resins containing the protected
amino acid sequences were used in the coupling reaction to the
porphyrin derivatives. The H-peptide-resin (0.025 mmol) was swelled
in DMF for 1 h and then washed with DMF. To the peptidyl resin was
added 600 μL of a DMF−CH2Cl2 (1:1, v/v) solution containing 0.05
mmol of porphyrin (1b, 2b or 3b), 0.05 mmol of diisopropylcarbo-
diimide, and 0.05 mmol of 1-hydroxybenzotriazole. The reaction
mixture was shaken overnight and then filtered to remove the excess of
reagents. The resin was repeatedly washed with DMF and CH2Cl2,
until the filtrate was colorless, and then dried under vacuum. Cleavage
and deprotection was carried out by treatment of the resin with a
mixture of TFA−triisopropylsilane−water (95:2.5:2.5 by volume) for
1.5 h at rt. The resin was filtered and washed with TFA, and the
filtrates were combined and reduced under vacuum to a small volume.
Addition of cold ether yielded a green precipitate, which was
repeatedly washed with ether and dried under vacuum. The conjugates
EXPERIMENTAL SECTION
■
General Methods. All chemicals were commercial products of the
best grade available, and unless otherwise indicated, they were used
directly without further purification. The starting porphyrins, 5-(4-
carboxyphenyl)-10,15,20-triphenylporphyrin (1b),42 9-(glutaric meth-
ylesteramide)-2,7,12,17-tetraphenylporphycene (2a),29 and 5-(4-car-
boxyphenyl)-10,15,20-tris(4-pyridyl)porphyrin (3b) and its tris-N-
methylpyridinium iodide (4b),28 were prepared according to literature
procedures. 9-Fluorenylmethoxycarbonyl (Fmoc)-amino acids and all
other chemicals for the solid-phase synthesis were supplied by Sigma-
Aldrich. Fmoc-Leu-Wang resin was purchased from Novabiochem
(Merck Biosciences). Analytical HPLC separations were carried out on
1060
dx.doi.org/10.1021/jm301509n | J. Med. Chem. 2013, 56, 1052−1063